Experiments on the P 388 D1 cell Line (48 h exposure) demonstrate that [ 1.2-bis-(fluomphenyl)ethylenediamine]platinum(II) complexes are comparably active on the. cell number and 3H-thynidine incorporation, irrespective of the position of the fluorine atom (ortho, meta, or para) and the nature of the "leaving group" (Cl-or H20). However, the. compounds of the R,R/S,S series are more active than those of the R,S series and comparable to cisplatin. In the "tumor colony forming assay" the RNS.S configurated compounds are about ten times as active as cisplatin. The RJUS,S conligurated diaqua[l,2-bis(4-fluomphenyl)ethylenediamine]platinum(II) salts reach theii half maximum effect more readily (tin I 1.6 h) than their R,S configurated The antitumor activity of diastereomeric dichloro( 1,2-diphenylethylenediamine)platinum(II) complexes is strongly influenced by substituents in para positions of both benzene rings. Among various residues fluorine proved to be of special interest'). The R,R/S,S configurated [1,2-bis(4-fluoropheny1)ethylenediaminel-dichloroplatinum(II) complex (15) was the most active. In part I of this publication we have described the synthesis of the diastereomeric ortho, meta and para fluoro substituted dichloro( 1,2diphenylethylene-diamine)platinum(II) complexes 13 to 18 and of their more water soluble diaquaplatinum(II) salts 25 to 32*). In part II of this publication we investigate the influence of the F-position, the configuration and the leaving group (Cl-or H 2 0 ) on the antitumor activity against P 388 leukemia in vitro.
The antitumor activity of diastereomeric dichloro( 1,2-diphenylethylenediamine)platinum(II) complexes is strongly influenced by substituents in para positions of both benzene rings. Among various residues fluorine proved to be of special interest'). The R,R/S,S configurated [1,2-bis(4-fluoropheny1)ethylenediaminel-dichloroplatinum(II) complex (15) was the most active. In part I of this publication we have described the synthesis of the diastereomeric ortho, meta and para fluoro substituted dichloro( 1,2diphenylethylene-diamine)platinum(II) complexes 13 to 18 and of their more water soluble diaquaplatinum(II) salts 25 to 32*). In part II of this publication we investigate the influence of the F-position, the configuration and the leaving group (Cl-or H 2 0 ) on the antitumor activity against P 388 leukemia in vitro. 
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Compd. (Table 1) .
In addition to these experiments 13 to 18 were comparatively tested with cisplatin in the in vitro soft agar tumor clonogenic assay (TCA) to determine their effect on the colony forming ability of P 388 D1 leukemia cells (i.e. the loss of their stem cell function in the presence of drugs). Stem cells (e.g. the hematopoietic stem cell), which are responsible for maintaining the integrity and continued survival of any particular cell population, are capable of an indefinite number of divisions. Unlike to this the differentiated cells lack this unlimited capacity of proliferation3). In accordance with the stem cell conception it is assumed that in cancer diseases so called tumor stem cells are responsible for tumor growth or regrowth after treatment and also for the forming of metastases. Therefore, it is the tumor stem cell population that must be eradicated to obtain curative cancer chemotherapy4). Clonogenic tumor cells in TCA are considered to be closely related to tumor stem cells in situ, therefore, the predictive value of this assay for a possible in vivo activity should be superior to other in vitro assays.
In the TCA, too, the R,R/S,S configurated compounds 13 to 15 as well as the R,S configurated compounds 16 to 18
proved to be equiactive on the P 388 D1 leukemia cell line irrespective of the position of the fluorine atoms in the phenyl rings. However, the compounds of the R,R/S,S series are much more active than those of the R,S series. The cytotoxic effect of platinum complexes is not the result of an inhibition of the DNA synthesis in the S phase of the cell cycle (up to now generally accepted as the critical step in cisplatin-induced toxicity) but of a persistent (i.e. irreversible) G2 arrest, as shown by Eusrman and Soremod). Furtheron it is proposed that the G2 arrest results from the inability of the cells to transcribe genes required for the passage into mitosis6).
The lack of differences in activity between analogous cisPtA2C12 and cis[PtA2(H20)2]X complexes (A5 1,2-bis (2-,3-, and 4-fluoropheny1)ethylenediamine; X: S042-or 2 NO3-) is surprising since, as a rule, the change from the nonionic dichloroplatinum(lI) complex to the ionic diaquaplatinum(II) complex leads to a decrease in antitumor activity. An example for a drastic change of efficacy is provided by cis-F't(NH3)2C12 in which the substitution of C1 by H20 is accompanied by a loss of activity on the L 1210 leukemia of the mouse7). In contrast to this, diaquaplatinum(II) complexes with spacious, lipophilic ligands like cis-[Pt(DAC) (H20)2] (NO3)* (DAC: 1,2-diaminocyclohexane) show tumor inhibiting properities (L 1210 leukemia, mouse) which are comparable to those of the analogous dichloroplatinum(II) complexes7).
In these complexes presumably two factors are responsible for the appearance of antitumor activity:
1. The steric shielding of Pt. It impedes the reaction with bionucleophils. Therefore, the inactivation of the complex during its transport to the tumor cell is retarded.
2. The hydrophobic character. It facilitates the penetration of the drug across the plasma membrane of the tumor cell. Both factors lead to therapeutically active drug levels in the tumor cell.
According to the rate of hydrolysis, two classes of platinum@) complexes can be observed Class 1 complexes in which the leaving group is immediately substituted by HzO (e.g. [c~s-P~Az(HzO)(SO~)].HZO in which the SO4 ligand is bonded to the Pt through one of its oxygen atoms; regarding to the coordination of SO4 to P t see below). Class 2 complexes, in which the exchange of the leaving group for HzO takes 1 to several h (e.g. cis-PtAzClz).
Compounds of class 1, e.g. 30, are -as mentioned -only antitumor active, if their amine ligand causes a steric shielding of pt, thereby hindering the reaction with bionucleophils during the transport to the tumor cell. Unlike to this, compounds of class 2 are also antitumor active, if they contain small amine ligands like N H 3 . Class 2 complexes are weakly-reactive prodrugs which are slowly hydrolized into the active drugs (cis[PtA~(H20)2]~+). Therefore, the inactivation of class 2 complexes by bionucleophils is impeded during the transport to the tumor cell. They probably pass the cell membrane in the form of non-ionic cis-PtAzX, followed by an activation in the cell (e.g. exchange of X by Hz0). In the case of cisplatin hydrolysis is supposed to be suppressed under the conditions of the high extracellular C1-concentration (0.103 M), while the low C1-level (0.004 M) in the cytoplasm facilitates the Cl-/I-IzO exchange. These findings infer that the kinetic behavior of platinum@) complexes in the reaction with nucleophils is essential for the antitumor activity, therefore, too fast or too slowly reacting complexes are weakly active.
We think that the development of water soluble and hence therapeutically better applicable platinum(I1) complexes with [ci~-PtA~(H20)2]X structure is feasible. This requires the choice of appropriate amine ligands which do retard the inactivation of the drug via reaction with bionucleophils during the transport to the tumor cell but still allow the interaction with DNA, which is essential for the antitumor activity.
In the following we describe the influence of the leaving group (HzO or Cl-) and the configuration of C-1 and C-2 of the 1,2-bis(4-fluorophenyl)ethylenediamine ligand on the time-dependent inhibition of the 3H-thymidine incorporation in the P 388 D1 leukemia cell culture.
In the R,R/S,S confgurated series a considerably faster onset of action of the equally active diaquaplatinum(II) sulfate (27) and nitrate (31), tln G 1.6 h (time (h) required for a 50 9% inhibition), is observed compared to dichloroplatinum@)-compound 15, tln G 3.3 h, (Figure 1) . This difference is caused by a slow hydrolysis of 15 to f o m the active species [cis-PtAz(HzO)2]X, which is responsible for the reaction with DNA.
In the case of 31, whose nitrate residues are directly coordinated with R2+, an exchange of NO3 by H20 takes place immediately after dissolution in water. The same is true for a sulfate residue in compound 27 which is coordinated with Pt.
According to the elemental analysis, 27 contains two molecules of wate?). Besides the structural formula IIIa, structure IIIb (unidentate complex) must be discussed (see also Part I of this publication). A compound of type IIIb (structurally analogous to 27) was obtained by Rochon and Melanson8) by the reaction of (N,N'-dimethylethylenediamine)diiodoplatinum(II) with AgzS04. The structure of [aqua(N,N'-dimethylethylenediamine)sulfatoplatinum(II)]hydrate was confirmed by Xray analysis8). In this molecule the coordinated water forms two strong hydrogen bonds, donating one proton to an oxygen atom of the sulfate ligand and the other proton to the lattice water oxygen. The relationship between the HzO molecules and the sulfate residue contributes to complex stability.
The question whether 27 is described by formula IIIa or and R,S configurated complexes can be explained by a stronger steric hindrance caused by the axially standing phenyl ring of the latter complexes impeding the approach to DNA, as has been discussed elsewhexdo."). In the case of the R,R/S,S configurated complexes only the conformation is favored in which both phenyl rings are equatorially arranged2). Accordingly, different kinetics have been reported for the reactions of the diastereomeric [ 1,2-bis(4-fluorophenyl)ethylenediamine]sulfatoplatinum(II) complexes 27 and 30 with salmon testis DNA13). In these experiments, DNA synthesis catalysed by E. coli-DNA polymerase I was inhibited by the coordination reaction of the platinum(II) complexes with DNA, presumably in N-7 positions of guanines. The kinetics of inhibition followed the formation of monoadducts, and was faster in the case of the racemate 27 than of the meso-form 30. (Table 4) . hint at possible differences in the uptake of ionic and non-ionic species by the tumor cells.
While the dichloroplatinum@) complex 15 yields only a moderate further decrease in DNA synthesis during the reincubation, a strong effect is observed in the case of the diaquaplatinum(II) complexes 27 and 31. This finding could be explained by a higher intracellular concentration caused by a faster uptake of the ionic diaquaplatinum(II) complexes 27 and 31 by the tumor cells compared to the nonionic dichloroplatinum@) complex E l 4 ) . This is even more surprising since an inactivation of the reactive diaquaplatinum(II) species by nucleophils in the medium must be expected. With the dichloroplatinum(II) species this inactivation process is only possible after hydrolysis. Apparently, the reaction of 27 and 31 with nucleophils is strongly retarded due to steric conditions. It may also be that distinct mechanisms are responsible for the permeation of cisplatin and [ 1,2-bis(4-fluorophenyl)ethylenediamine]-diaquaplatinum(II) complexes across the cell membrane. Such differences can be the basis of an activity of the [1,2-bis(4-fluorophenyl)ethylenediamine]platinum(II) complexes against cisplatin-resistant tumors, as is pointed out in the following.
The development of resistance toward cisplatin as a result of alterations in drug accumulation has been di~cussed'~). Although it is widely accepted that platinum(II) complexes enter the cell by diffusion along a concentration gradient'@, there is evidence that the transport of cisplatin is carrier mediated. Byfield and Cal~bro-Jones'~~'~) demonstrated that amino acids protect cells against cisplatin, suggesting that the latter is also taken up by an amino acid transport mechanism.
The resistance to cisplatin could stem from somatic mutations that yield cells whose membrane carriers are either fewer in number or have reduced drug affinity17). These alterations lead to a minor trans-membrane transport. Hints at this mechanism of resistance are given by uptake experiments with a L 1210 leukemia cell line which show a 6.6 fold resistance to cisplatin. They demonstrated a decreased accumulation of cisplatin in the cells"). The observation that a L 1210 leukemia cell line primarily resistant to melphalan is cross-resistant to cisplatin supports also this mode of action, since the melphalan resistance was accompanied by a decrease in the melphalan concentration within the cells'').
Because of the suggested differences between cisplatin and the diaquaplatinum(II)complexes 27 and 31 concerning the mechanism of their trans-membrane transport, an effect of these new complexes against cisplatin resistant tumors is conceivable. An indication of such a therapeutic applicability is the finding that of mice bearing cisplatin-resistant Ehrlich ascites tumors about 70 % are cured by [R,R/S,S-1,2-bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum @ I ) (3 x 5 m@g ip), a substance which is structurally related to 27 and 31 (Seeber, unpublished) . Compounds 27 and 31 might be "carrier-independent" platinum complexes, which penetrate the tumor cell membrane by simple diffusion. "Carrier-independent" drugs are of therapeutic interest since: 1. they show a reduced tendency to induce resistance") and a high antitumor activity in vivoZ2) and 2.
they are known to lack cross-resistance to "carrier-dependent" platinum(II) complexes like ~isplatin'~*~~)), Treatment schedules in which such "carrier-independent" platinum(II) complexes are combined with cisplatin or another "carrierdependent" platinum@) complex are predicted to be most useful, as they would minimize the outgrowth of drug-resistant tumors and, therefore, should elongate the remission period.
In order to verify the lack of cross resistance to cisplatin the R,R/S,S configurated [ 1,2-bis(fluorophenyl)ethylenediaminel-platinum(II) complexes 13 to 15 were evaluated on the cisplatin-sensitive and -resistant Ehrlich ascites tumor of the mouse. Compounds 13 and 14 were inactive on the cisplatin-sensitive Ehrlich ascites tumor at a dose of 3 x 10 mg/kg and 3 x 20 mgkg (Figures 3 and 4 15 caused a marked effect on a L 1210 cell line, which is 100 fold resistant to cisplatin. The determined ED50 value of 1,4 (pM) corresponds only to a 7 fold resistance. However, a surprisingly high resistance against 15 (ED50 (pM = 37, corresponding to a 185 fold resistance) was found in a DAC-resistant L 1210 cell line. This line is about 40 fold resistant to DAC-Pt(II) complexes. This suggests that 15 is closer related to DAC-Pt(II) complexes than to cisplatin regarding its mode of action.
The resistance of the above described new L 1210 cell lines against platinum(II) complexes has in part been attributed to an enhanced repair of DNA-Pt-le~ions'~.~~). However, reduced drug accumulation also seems to play a role. In this connection it is also worthy of note that the DAC resistant L 1210 cells exhibit a pronounced reduction in accumulation of (1,2-diaminocyclohexanene)platinum(II) complexes28). This feature may be an important factor in the low sensibility of the DAC resistant L 1210 cell line against 15.
These and other results2') in the class of (1,2-&phenyle-thylenediamine)platinum(II) complexes show that the activity against cisplatin-resistant tumors depends on the nature and position of the ring substituents and also of the ligand configuration.
In further publications we well inform on the development of new platinum complexes for the second line therapy of tumor diseases after development of resistance against cisplatin.
This work was supported in the initial phase by the "Wilhelm SanderStiftung", and then by the Bundesministerium fiir Forschung und Technologie. Federal Republic of Germany, grant 03 8512/9. Thanks are also due to the Deutsche Forschungsgememeinschaft, the "Walter Schulz-Stiftung", the "Matthias Lackas-Stiftung fiir Krebsforschung" and the "Fonds der Chemischen Industrie" for financial support. The technical assistance of M. Beer, F. Birk, S. Dehen, B . Hofmann. P. Pistor. P. Richthammer, and C . Wenzlick is gratefully acknowledged.
Experimental Part

P 388 Dl Leukemia cell culture experiments
Standard conditions. The P 388 DI cells (ATCC CCL 46) were grown in static suspension culture in RPMI 1640 medium (Gibco) supplement with 10 % heat-inactivated horse serum (Boehringer), 10 mM HEPES buffer (Biochrom), 2 mM glutamine (Biochrom) and NaHC03 (0.85 @) in a humidified atmosphere of 5 % COz in air at 37'C. Stock cultures were grown in 75 cm2 culture flasks (Falcon) . The diaquaplatinum(I1) complexes were dissolved in bidistilled water or methanol, the dichloroplatinum(I1) complexes in DMF. The test compounds were added as 5MT or 1000-fold concentrated stock solutions.
Determination of EDSo
2 ml of cell suspension (7-8.104 cells/ml) were placed in glass centrifuge tubes sealed with aluminium caps and incubated under standard conditions. After 4 h incubation cells were counted with a Coulter Counter (Coulter Electronics Ldt) and the test compounds were added. 2 h prior to the end of the experiment the cells were labeled with 0.3 pCi 3H-thymidine (40-60 Ci/mmol, New England Nuclear) per tube. After 48 h 0.5 ml of culture were used to determine cell numbers, the remaining portion was centrifuged and washed twice with ice-cold PBS (Phosphate buffered saline: NaCl (8 g), KCl (0.2 8). NazHPO~HzO (0.15 g) and KHzP04 (0.2 g) in 1 L of HzO). The pellet was resuspended in 1 ml water and the cells were broken up by sonication using a Branson sonifier. To the sonicated cells 4 ml 10 9% TCA was added and the precipitate was filtered over 0.45 pm filter (Sartorius). The 'H-thymidine incorporation was determined in 
Time-dependent of inhibition of 'H-thymidine incorporation
Cell suspension (2 ml) were placed in glass centrifuge tubes sealed with aluminium caps. For incubation times up to 6 h the initial cell concentration was 2.4-2.6 . 1 6 cells/ml. When cell cultures were incubated up to 48 h the initial cell number per ml was 1.1-1.4.16. The test compounds were added in a final concentration of l.10-5 M and 20 min prior to the end of the experiment the cells were labeled with 1 pCi 3H-thymidine per tube.
The 3H-thymidine incorporation was stopped rapidly by shaking the tubes in ice water. The 3H-thymidine was determined as described above. For % T/C calculation control cultures were treated identically.
Long term effect on the 3H-thymidine incorporation afer short drug incubation times Cells were incubated with test compounds for varying periods of time and spun down at 500 g. The pellet was washed with medium and the cells were resuspended and reincubated in drug-free culture medium. The %I-thymidine labeling procedure was performed as described above.
Count of viable cell?4'
The number of viable cells was determined by means of trypan blue exclusion staining. Technique: w a n blue stock solution (Sigma) was diluted with PBS to an end concentration of 0.16 %. Equal volumes of diluted stain and cell suspension were mixed. The number of cells not being stained Drug trearmentfor 48 h. The volume which contains 3 x lo4 cells was determined in the control. This volume was used as inoculum as well for the control as for the test. Further conditions c. f. 1 h experiments.
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SOB agar cloning method
With slight modifications, the clonogenic assay was performed according to Hamburger and Salomnz'. Briefly, the tumor cells were suspended in upperlayer consisting of 0.3 8 agar in enriched CMRL 1066 (Gibco) supplemented with 15 96 heat inactivated fetal calf serum (FCS; Boehringer), penicillin (final concentration 100 U/ml), streptomycin (100 pg)ml). glutamine (2 mM), CaClz (4 mM), ascorbic acid (0.3 mM), bovine insulin (2 Urn), asparagine (0.5 mM) and mercaptoethanol (50 pM; the latter substances all obtained from Sigma). 1 ml of the resultant mixture was pipetted onto 1 ml underlayer in plastic petri dishes (Falcon plastics); this was done in triplicate for each of at least 3 different drug concentrations. The underlayer consisted of 0.5 % agar in enriched McCoy's 5A medium (Gibco) supplemented with 15 % FCS. Napyruvate (final concentration 2 mM); Lserine (0.4 mM), glutamine (2 mM), penicillin (100 U/ml), streptomycin (100 pg/ml), tryptic soy broth [ O S % (w/v)] and asparagine (0.75 mM, the latter substances all obtained from Sigma). The plates were incubated at 37'C in an atmosphere of 5 8 COz and 100 % humidity, after microscopical control had confirmed that there were no artificial cell-aggregates. The number of tumor cell colonies (aggregates of more than 32 cells) was counted 10-14 days after plating by means of an inverted microscope. Drug effects were expressed as the percentage of inhibition of colony formation compared to the untreated dishes.
Ehrlich Ascites Tumos6'
The different resistant Ehrlich ascites tumor lines (wild type and Cisplatin-resistant) are maintained by routine passage in female NMRI mice. For the evaluation of the therapeutic activity groups of ten female mice were Suspension cultures are grown in McCoy's 5a (modified) medium supplemented with NaHCO3 (2.2 u), penicillin (250 U/ml), streptomycin (250 U/ml). fungizone (1pg)ml) and 16 % calf serum. For growth inhibition
